Baxter International Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Baxter International Inc.
Wockhardt Aims For $12m Annual Savings Through US Restructuring
Wockhardt expects to save up to $12m through restructuring its US business, eyeing up a potential return to profitability by 2025.
Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns
Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.
iPLEDGE REMS: US FDA Advisory Cmte. Supports Relaxing Restrictions But Wants More Data
Panel favors elimination of 19-day lockout after missed prescription pickup and continuation of at-home pregnancy tests. Members call for more data from isotretinoin sponsors on why acne patients are not participating in pregnancy registry and on disparities by race and ethnicity.
ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach
Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Drug Delivery
- Infusion Therapy Equipment and Supplies
Surgical Equipment & Devices
- Surgical Sealants
- Other Names / Subsidiaries
- AesRX LLC
- Althin Medical A.B.
- Chatham Therapeutics
- Cheetah Medical
- Claris Injectables Limited
- Fusion Medical Technologies, Inc.
- Gambro AB
- Prism Pharmaceuticals, Inc.
- Renal Therapy Services
- SIGMA International Geneeral Medical Apparatus
- SuppreMol GmbH
- Synovis Life Technologies, Inc.
- Wound Care Technologies, Inc.
- Baxter Healthcare Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.